阿维A、环孢素、富马酸酯和甲氨蝶呤治疗中重度银屑病患者的有效性和持续性:一项来自BADBIR的队列研究
基于BADBIR前瞻性多中心药物警戒登记研究,纳入2007至2021年间首次使用阿维A、环孢素、富马酸酯或甲氨蝶呤且随访≥6个月的≥16岁中重度银屑病患者共5430例。阿维A组达到aPASI≤2的比例为21%,低于环孢素组的34%、富马酸酯组的29%和甲氨蝶呤组的32%。甲氨蝶呤12个月持续率估计为46.1%,高于阿维A的31.9%、环孢素的30.0%和富马酸酯的35.0%。
要点
- 阿维A达到aPASI≤2的比例为21%,低于环孢素34%、富马酸酯29%和甲氨蝶呤32%。
- 甲氨蝶呤12个月持续率估计为46.1%,高于阿维A31.9%、环孢素30.0%和富马酸酯35.0%。
- 既往非生物系统治疗史、男性、合并症和饮酒与治疗无效风险相关。
核心结论
- 阿维A、环孢素、富马酸酯和甲氨蝶呤的真实世界有效性和持续性普遍较低。
- 既往非生物系统治疗史、男性、合并症和饮酒是治疗无效的风险因素。
研究设计与样本
- 研究分析了英国皮肤科医师协会生物制剂和免疫调节剂登记(BADBIR)的数据,该登记为前瞻性、多中心药物警戒登记,纳入接受生物制剂和/或传统系统治疗的中重度银屑病患者。
- 纳入标准为2007年至2021年间首次接受阿维A、环孢素、富马酸酯或甲氨蝶呤治疗、年龄≥16岁且随访≥6个月的患者,共5430例。
- 有效性定义为治疗开始后≥4周至停药日期间报告的绝对银屑病面积和严重程度指数(aPASI)≤2。
- 采用多变量logistic回归模型估计达到aPASI≤2的调整比值比(aOR),并使用灵活参数模型获得停药原因的生存估计及95%置信区间(CI),结果基于多重插补数据。
主要发现
- 共纳入5430例患者,其中阿维A组1023例(19%)、环孢素组1401例(26%)、富马酸酯组347例(6%)、甲氨蝶呤组2659例(49%)。
- 达到aPASI≤2的患者比例:阿维A组118例(21%),低于环孢素组233例(34%)、富马酸酯组43例(29%)和甲氨蝶呤组372例(32%)。
- 与治疗无效相关的因素包括:阿维A组既往非生物系统治疗史(aOR 0.64,95% CI 0.42-0.96),甲氨蝶呤组男性(aOR 0.58,95% CI 0.46-0.74),合并症(aOR 0.70,95% CI 0.51-0.97),环孢素组饮酒(≤14单位/周)(aOR 0.70,95% CI 0.50-0.98)。
- 12个月时因所有原因停药的持续率生存估计:甲氨蝶呤组46.1(95% CI 44.0-48.3),阿维A组31.9(95% CI 29.4-34.7),环孢素组30.0(95% CI 27.5-32.4),富马酸酯组35.0(95% CI 29.9-40.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world data evaluating effectiveness and persistence of systemic therapies for patients with psoriasis are limited. Objectives To determine the effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters (FAEs) and methotrexate in patients with moderate-to-severe psoriasis. METHODS: Data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), a prospective, multicentre pharmacovigilance register of patients with moderate-to-severe psoriasis receiving biologic and/or conventional systemic therapies, were analysed. Eligible patients were ≥ 16 years of age receiving a first course of acitretin, ciclosporin, FAEs or methotrexate between 2007 and 2021 with ≥ 6 months' follow-up. Effectiveness was defined as achieving absolute Psoriasis Area and Severity Index (aPASI) ≤ 2 reported ≥ 4 weeks after treatment start date until date of cessation. To identify baseline clinical variables associated with treatment effectiveness, we used multivariable logistic regression models estimating the adjusted odds ratio (aOR) of achieving aPASI ≤ 2. To describe drug persistence associated with ineffectiveness, occurrence of adverse events or other reasons for discontinuation, survival estimates with 95% confidence intervals (CIs) were obtained using a flexible parametric model. Results were obtained using multiple imputed data. RESULTS: In total, 5430 patients were included in the analysis. Overall, 1023 (19%) patients were receiving acitretin, 1401 (26%) patients were on ciclosporin, 347 (6%) patients were on FAEs, and 2659 (49%) patients were receiving methotrexate at registration. The proportion of patients who achieved aPASI ≤ 2 was lower for those treated with acitretin [n = 118 (21%)] compared with those receiving ciclosporin [n = 233 (34%)], FAEs [n = 43 (29%)] and methotrexate [n = 372 (32%)]. Factors associated with ineffectiveness included prior experience to previous nonbiologic systemic therapies (acitretin) (aOR 0.64, 95% CI 0.42-0.96), male sex (methotrexate) (aOR 0.58, 95% CI 0.46-0.74), comorbidities (aOR 0.70, 95% CI 0.51-0.97) and alcohol consumption (≤ 14 units per week) (ciclosporin) (aOR 0.70, 95% CI 0.50-0.98). Persistence associated with all reasons for discontinuation showed better survival for methotrexate compared with acitretin, ciclosporin and FAEs cohorts at 12 months [survival estimate 46.1 (95% CI 44.0-48.3), 31.9 (95% CI 29.4-34.7), 30.0 (95% CI 27.5-32.4) and 35.0 (95% CI 29.9-40.9), respectively]. CONCLUSIONS: The real-world effectiveness and persistence of acitretin, ciclosporin, FAEs and methotrexate were generally low. Previous nonbiologic systemic therapies, male sex, comorbidities and alcohol consumption were risk factors associated with treatment ineffectiveness.
引用
- Alabas OA, Mason KJ, Yiu ZZN, et al. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. Br J Dermatol. 2023. PMID: 36763783. doi:10.1093/bjd/ljad004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。